Drug Trial Radar · NCT02087904
A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Jun 4, 2014
Primary completion
Jun 7, 2016
Study completion Dec 13, 2016
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 35 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2a, multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic effect of ABT-981 in patients with symptomatic, radiographic, and inflammatory knee osteoarthritis.
Conditions
- Knee Osteoarthritis
- Medial Compartment Knee Osteoarthritis
Interventions
ABT-981Biological
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16Time frame: Baseline, Week 16
- Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26Time frame: Baseline, Week 26
- Change From Baseline in Effusion Volume of the Index Knee at Week 26Time frame: Baseline, Week 26
- Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26Time frame: Baseline, Week 26
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.